• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

探索成人接受生物治疗后重度哮喘临床缓解的定义和预测因素。

Exploring Definitions and Predictors of Severe Asthma Clinical Remission after Biologic Treatment in Adults.

机构信息

Pneumology Service, Lucus Augusti University Hospital, EOXI Lugo, Monforte, Cervo, Spain.

Observational and Pragmatic Research Institute, Singapore, Singapore.

出版信息

Am J Respir Crit Care Med. 2024 Oct 1;210(7):869-880. doi: 10.1164/rccm.202311-2192OC.

DOI:10.1164/rccm.202311-2192OC
PMID:38701495
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11506911/
Abstract

There is no consensus on criteria to include in an asthma remission definition in real life. Factors associated with achieving remission after biologic initiation remain poorly understood. To quantify the proportion of adults with severe asthma achieving multidomain-defined remission after biologic initiation and identify prebiologic characteristics associated with achieving remission that may be used to predict it. This was a longitudinal cohort study using data from 23 countries from the International Severe Asthma Registry. Four asthma outcome domains were assessed in the 1 year before and after biologic initiation. defined remission cutoffs were: 0 exacerbations/yr, no long-term oral corticosteroid (LTOCS), partly/well-controlled asthma, and percent predicted FEV ⩾ 80%. Remission was defined using two (exacerbations + LTOCS), three (+control or +lung function), and four of these domains. The association between prebiologic characteristics and postbiologic remission was assessed by multivariable analysis. A total of 50.2%, 33.5%, 25.8%, and 20.3% of patients met criteria for two-, three- (+control), three- (+lung function), and four-domain remission, respectively. The odds of achieving four-domain remission decreased by 15% for every additional 10 years of asthma duration (odds ratio, 0.85; 95% confidence interval, 0.73-1.00). The odds of remission increased in those with fewer exacerbations per year, lower LTOCS daily dose, better control, and better lung function before biologic initiation. One in five patients achieved four-domain remission within 1 year of biologic initiation. Patients with less severe impairment and shorter asthma duration at initiation had a greater chance of achieving remission after biologic treatment, indicating that biologic treatment should not be delayed if remission is the goal.

摘要

在现实生活中,对于纳入哮喘缓解定义的标准尚未达成共识。对于生物制剂治疗后实现缓解的相关因素仍知之甚少。本研究旨在定量评估生物制剂治疗后重度哮喘患者达到多维度定义缓解的比例,并识别与缓解相关的生物学前特征,这些特征可能有助于预测缓解。这是一项使用来自国际重度哮喘注册研究(International Severe Asthma Registry)的 23 个国家数据的纵向队列研究。在生物制剂治疗前和治疗后 1 年评估了 4 个哮喘结局领域。缓解的定义使用了以下 2 个(加重事件+口服激素)、3 个(+控制或+肺功能)和 4 个领域的缓解标准。通过多变量分析评估了生物学前特征与生物制剂治疗后缓解之间的关系。分别有 50.2%、33.5%、25.8%和 20.3%的患者符合 2 个、3 个(+控制)、3 个(+肺功能)和 4 个领域缓解标准。与实现 4 个领域缓解相比,哮喘病程每增加 10 年,达到 4 个领域缓解的可能性降低 15%(比值比,0.85;95%置信区间,0.73-1.00)。每年加重次数更少、口服激素日剂量更低、控制更好和肺功能更好的患者缓解可能性更高。有 1/5 的患者在开始生物制剂治疗后 1 年内达到了 4 个领域的缓解。在开始生物治疗时,病情较轻且哮喘病程较短的患者在生物治疗后缓解的机会更大,这表明如果缓解是目标,则不应延迟生物治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60b9/11506911/7a4f0abcfef1/rccm.202311-2192OCf4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60b9/11506911/cc5caddfca16/rccm.202311-2192OCf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60b9/11506911/e3d855817ecb/rccm.202311-2192OCf2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60b9/11506911/c0b788d698fa/rccm.202311-2192OCf3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60b9/11506911/7a4f0abcfef1/rccm.202311-2192OCf4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60b9/11506911/cc5caddfca16/rccm.202311-2192OCf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60b9/11506911/e3d855817ecb/rccm.202311-2192OCf2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60b9/11506911/c0b788d698fa/rccm.202311-2192OCf3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60b9/11506911/7a4f0abcfef1/rccm.202311-2192OCf4.jpg

相似文献

1
Exploring Definitions and Predictors of Severe Asthma Clinical Remission after Biologic Treatment in Adults.探索成人接受生物治疗后重度哮喘临床缓解的定义和预测因素。
Am J Respir Crit Care Med. 2024 Oct 1;210(7):869-880. doi: 10.1164/rccm.202311-2192OC.
2
Exploring Definitions and Predictors of Response to Biologics for Severe Asthma.探索严重哮喘对生物制剂反应的定义和预测因素。
J Allergy Clin Immunol Pract. 2024 Sep;12(9):2347-2361. doi: 10.1016/j.jaip.2024.05.016. Epub 2024 May 19.
3
Impact of pre-biologic impairment on meeting domain-specific biologic responder definitions in patients with severe asthma.在严重哮喘患者中,预先存在的生物标志物异常对符合特定生物标志物应答定义的影响。
Ann Allergy Asthma Immunol. 2024 May;132(5):610-622.e7. doi: 10.1016/j.anai.2023.12.023. Epub 2023 Dec 25.
4
Association between pre-biologic T2-biomarker combinations and response to biologics in patients with severe asthma.严重哮喘患者中 T2 生物标志物组合与生物制剂应答之间的关联。
Front Immunol. 2024 Apr 19;15:1361891. doi: 10.3389/fimmu.2024.1361891. eCollection 2024.
5
Real-world biologics response and super-response in the International Severe Asthma Registry cohort.真实世界生物制剂应答和超应答在国际严重哮喘注册研究队列中的表现。
Allergy. 2024 Oct;79(10):2700-2716. doi: 10.1111/all.16178. Epub 2024 Jun 22.
6
Comparative effectiveness of anti-IL5 and anti-IgE biologic classes in patients with severe asthma eligible for both.适合接受两种药物治疗的重度哮喘患者中抗白细胞介素 5 类和抗免疫球蛋白 E 类生物制剂的疗效比较。
Allergy. 2023 Jul;78(7):1934-1948. doi: 10.1111/all.15711. Epub 2023 Mar 27.
7
Clinical Response and Remission in Patients With Severe Asthma Treated With Biologic Therapies.接受生物疗法治疗的重度哮喘患者的临床反应与缓解情况。
Chest. 2024 Feb;165(2):253-266. doi: 10.1016/j.chest.2023.10.046. Epub 2023 Nov 3.
8
Variables predicting clinical remission among adults with severe asthma treated with biologic agents.预测接受生物制剂治疗的重度哮喘成人达到临床缓解的变量。
Eur Ann Allergy Clin Immunol. 2024 Sep;56(5):219-226. doi: 10.23822/EurAnnACI.1764-1489.318. Epub 2023 Dec 6.
9
Comparison of Long-term Response and Remission to Omalizumab and Anti-IL-5/IL-5R Using Different Criteria in a Real-life Cohort of Severe Asthma Patients.在重度哮喘患者的真实队列中,使用不同标准比较奥马珠单抗和抗IL-5/IL-5R的长期反应与缓解情况。
Arch Bronconeumol. 2024 Jan;60(1):23-32. doi: 10.1016/j.arbres.2023.11.011. Epub 2023 Nov 22.
10
Clinical remission in severe asthma with biologic therapy: an analysis from the UK Severe Asthma Registry.生物疗法治疗重症哮喘的临床缓解:来自英国重症哮喘注册研究的分析。
Eur Respir J. 2023 Dec 14;62(6). doi: 10.1183/13993003.00819-2023. Print 2023 Dec.

引用本文的文献

1
Targeting Eosinophils in Asthmatic Inflammation: Benefits and Drawbacks.靶向哮喘炎症中的嗜酸性粒细胞:益处与弊端
J Inflamm Res. 2025 Sep 9;18:12421-12445. doi: 10.2147/JIR.S521238. eCollection 2025.
2
Detecting heart failure in severe asthma patients using speckle tracking echocardiography.使用斑点追踪超声心动图检测重度哮喘患者的心力衰竭
Crit Care. 2025 Aug 21;29(1):374. doi: 10.1186/s13054-025-05587-1.
3
Remission in Children Receiving Biologic Therapy for Severe Asthma.接受生物疗法治疗重度哮喘的儿童的病情缓解情况。

本文引用的文献

1
Impact of pre-biologic impairment on meeting domain-specific biologic responder definitions in patients with severe asthma.在严重哮喘患者中,预先存在的生物标志物异常对符合特定生物标志物应答定义的影响。
Ann Allergy Asthma Immunol. 2024 May;132(5):610-622.e7. doi: 10.1016/j.anai.2023.12.023. Epub 2023 Dec 25.
2
Pioneering a paradigm shift in asthma management: remission as a treatment goal.开创哮喘管理的范式转变:将缓解作为治疗目标。
Lancet Respir Med. 2024 Feb;12(2):96-99. doi: 10.1016/S2213-2600(23)00415-0. Epub 2023 Dec 7.
3
Clinical Response and Remission in Patients With Severe Asthma Treated With Biologic Therapies.
Pediatr Pulmonol. 2025 Aug;60(8):e71240. doi: 10.1002/ppul.71240.
4
Is Biologic Therapy an Effective Tool for Achieving Remission in Severe Asthma? A Retrospective Study in Central Romania.生物疗法是实现重度哮喘缓解的有效工具吗?罗马尼亚中部的一项回顾性研究。
Life (Basel). 2025 Jul 16;15(7):1113. doi: 10.3390/life15071113.
5
Achieving remission in severe asthma.实现重度哮喘的缓解
Chin Med J Pulm Crit Care Med. 2025 Jun 13;3(2):77-87. doi: 10.1016/j.pccm.2025.05.001. eCollection 2025 Jun.
6
Application of Biologics in the Treatment of Asthma in the Past Two Decades: A Bibliometric Analysis and Beyond.过去二十年生物制剂在哮喘治疗中的应用:文献计量分析及其他
J Asthma Allergy. 2025 May 19;18:779-793. doi: 10.2147/JAA.S514250. eCollection 2025.
7
Patient response and remission in respiratory disease: Special focus on severe asthma and chronic obstructive pulmonary disease.呼吸系统疾病中的患者反应与缓解:特别关注重度哮喘和慢性阻塞性肺疾病
J Int Med Res. 2025 May;53(5):3000605251340894. doi: 10.1177/03000605251340894. Epub 2025 May 20.
8
Pathway to Remission in Severe Asthma: Clinical Effectiveness and Key Predictors of Success with Benralizumab Therapy: A Real-Life Study.重度哮喘缓解途径:倍利珠单抗治疗的临床疗效及成功的关键预测因素:一项真实世界研究
Biomedicines. 2025 Apr 6;13(4):887. doi: 10.3390/biomedicines13040887.
9
Challenges and Opportunities in Achieving Asthma Remission.实现哮喘缓解的挑战与机遇
J Clin Med. 2025 Apr 20;14(8):2835. doi: 10.3390/jcm14082835.
10
What We Know to Date About Early Treatment With Biologics in Severe Asthma: A Scoping Review About the Use of Biologics in Severe Asthma and Possible Parallels With Early Rheumatoid Arthritis.目前我们对重度哮喘生物制剂早期治疗的了解:关于生物制剂在重度哮喘中的应用以及与早期类风湿关节炎可能相似之处的范围综述
Open Respir Arch. 2025 Feb 28;7(2):100418. doi: 10.1016/j.opresp.2025.100418. eCollection 2025 Apr-Jun.
接受生物疗法治疗的重度哮喘患者的临床反应与缓解情况。
Chest. 2024 Feb;165(2):253-266. doi: 10.1016/j.chest.2023.10.046. Epub 2023 Nov 3.
4
Adult Severe Asthma Registries: A Global and Growing Inventory.成人重度哮喘登记处:一份全球且不断增长的清单。
Pragmat Obs Res. 2023 Oct 20;14:127-147. doi: 10.2147/POR.S399879. eCollection 2023.
5
Clinical remission in severe asthma with biologic therapy: an analysis from the UK Severe Asthma Registry.生物疗法治疗重症哮喘的临床缓解:来自英国重症哮喘注册研究的分析。
Eur Respir J. 2023 Dec 14;62(6). doi: 10.1183/13993003.00819-2023. Print 2023 Dec.
6
Are We Ready for Asthma Remission as a Clinical Outcome?我们是否已做好将哮喘缓解作为临床结局的准备?
Chest. 2023 Oct;164(4):831-834. doi: 10.1016/j.chest.2023.04.028.
7
Effect of Tezepelumab on Lung Function in Patients With Severe, Uncontrolled Asthma in the Phase 3 NAVIGATOR Study.在 3 期 NAVIGATOR 研究中,特泽泊单抗对重度、未控制哮喘患者肺功能的影响。
Adv Ther. 2023 Nov;40(11):4957-4971. doi: 10.1007/s12325-023-02659-y. Epub 2023 Sep 19.
8
Consensus of an American College of Allergy, Asthma, and Immunology, American Academy of Allergy, Asthma, and Immunology, and American Thoracic Society workgroup on definition of clinical remission in asthma on treatment.美国过敏、哮喘与免疫学会、美国过敏、哮喘与免疫学会以及美国胸科学会工作组关于哮喘治疗中临床缓解定义的共识。
Ann Allergy Asthma Immunol. 2023 Dec;131(6):782-785. doi: 10.1016/j.anai.2023.08.609. Epub 2023 Sep 8.
9
Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients.生物制剂(美泊利珠单抗和奥马珠单抗)可诱导重度哮喘患者缓解。
Allergy. 2024 Feb;79(2):384-392. doi: 10.1111/all.15867. Epub 2023 Aug 25.
10
Clinical Remission in Severe Asthma: How to Move From Theory to Practice.重度哮喘的临床缓解:如何从理论转化为实践
Chest. 2023 Aug;164(2):296-298. doi: 10.1016/j.chest.2023.03.001.